ATOSSA THERAPEUTICS, INC.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
31
- −2 vs. Q1 2026
- Total value $2.6M
Superinvestors holding ATOS
0
- None of the superinvestors held ATOS at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by ATOS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2025 | May 21, 2025 | QUAY STEVEN CPresident & CEO | PPurchaseCommon Stock | +11.24K | $0.88 | +$9.89K | 13.9K | +422.7% | SEC |
| Mar 28, 2025 | Mar 26, 2025 | Remmel H. LawrenceDirector | PPurchaseCommon Stock | +10K | $0.70 | +$7K | 10.26K | +3,891.1% | SEC |
| Apr 11, 2024 | Apr 10, 2024 | Finn JonathanDirector | PPurchaseCommon Stock | +25K | $1.77 | +$44.25K | 25K | New position | SEC |
| Nov 17, 2023 | Nov 15, 2023 | WEAVER GREGORY LFormer EVP, CFO, & Director | SSaleCommon Stock | −50K | $0.65 | −$32.5K | 55 | −99.9% | SEC |
| Jun 20, 2023 | Jun 20, 2023 | WEAVER GREGORY LEVP & CFO | PPurchaseCommon Stock | +50K | $0.97 | +$48.5K | 50.06K | +90,909.1% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in ATOS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 361,747 | $698.17K | 0.00% | +12,651+3.6% | Added |
| AMERIPRISE FINANCIAL INC | 258,234 | $498.39K | 0.00% | +3,100+1.2% | Added |
| BlackRock, Inc. | 164,358 | $317.21K | 0.00% | +31,189+23.4% | Added |
| RENAISSANCE TECHNOLOGIES LLC | 132,043 | $254.84K | 0.00% | +23,036+21.1% | Added |
| GEODE CAPITAL MANAGEMENT, LLC | 92,382 | $178.34K | 0.00% | −4,679−4.8% | Reduced |